Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect and safety of liraglutide 3.0 mg in overweight or obese adults with type 2 diabetes mellitus treated with basal insulin
2015-005619-33Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity and type 2 diabetes mellitus (T2DM) comparing Liraglutide 3.0 mg arm with Placebo arm (2 arms). Primary endpoint: Change in body weight (%). Started Oct 2016; status: completed.
02
Drugs
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2015-005619-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005619-33.